Inventurus Knowledge Solutions Ltd.
IKS.NS
National Stock Exchange of India1,831.90
INR
-58.60
- -
Inventurus Knowledge Solutions Ltd.
IKS.NS
(National Stock Exchange of India)
Recent
price
1,831.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Inventurus Knowledge Solutions Ltd. (IKS.NS) is a healthcare technology company that provides AI-powered revenue cycle management (RCM) solutions and clinical data abstraction services to hospitals, health systems, and healthcare providers worldwide. The company offers a suite of products and services including its flagship AI-driven platforms for medical coding, denial management, quality abstraction, and prior authorization; proprietary tools such as HealthCode AI for autonomous coding, RevCycle AI for end-to-end RCM optimization, and QualityWorks for HCC and HEDIS abstraction; and managed services encompassing coding audits, compliance consulting, and analytics dashboards. Operating primarily in the United States, India, and the United Kingdom, Inventurus serves over 300 healthcare clients, targeting large hospital networks and post-acute care facilities with scalable, cloud-based solutions focused on improving financial performance and clinical outcomes. Founded in 2006 and headquartered in Mohali, Punjab, India, the company has grown through organic expansion and strategic investments without notable subsidiaries or parent relationships. In recent developments, Inventurus completed a significant funding round in 2024 led by Bain Capital, raising approximately $30 million to fuel AI platform enhancements and U.S. market penetration. The company launched HealthCode AI 2.0 in early 2025, introducing generative AI capabilities for 95% coding accuracy and real-time denial prevention, alongside a strategic partnership with a major U.S. health system to deploy RevCycle AI across 50 facilities. These initiatives mark a shift toward fully autonomous RCM, with expanded operations including a new delivery center in the Philippines announced in late 2024.